FDA approves treatment for rare bone marrow disorder

The FDA has approved Inrebic for the treatment of adult patients with certain types of myelofibrosis, a rare bone marrow disorder. 

Inrebic, a once-daily oral capsule, is the second treatment approved in the U.S. for myelofibrosis. The drug is manufactured by Impact Biomedicines, a subsidiary of Celgene.

The drug, a kinase inhibitor, targets treatment-naive myelofibrosis, a bone marrow disorder that disrupts the normal production of blood cells.

The approval is the first new treatment for the disease in nearly a decade. 

It also comes as a win for drug giant Bristol-Myers Squibb, which is finalizing its merger with Celgene. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars